Safety Evaluation of Tadalafil Treatment for Fetuses with Early-Onset Growth Restriction (TADAFER): Results from the Phase II Trial

Safety Evaluation of Tadalafil Treatment for Fetuses with Early-Onset Growth Restriction (TADAFER): Results from the Phase II Trial

Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor with a long half-life, high selectivity, and rapid onset of action. Because the safety of using PDE5 inhibitors as therapeutic agents for fetal growth restriction (FGR) has been a problem worldwide, this paper primarily focuses on the safety assess...

Full description

Bibliographic Details
Main Authors: Shintaro Maki, Hiroaki Tanaka, Makoto Tsuji, Fumi Furuhashi, Shoichi Magawa, Michiko K. Kaneda, Masafumi Nii, Kayo Tanaka, Eiji Kondo, Satoshi Tamaru, Toru Ogura, Yuki Nishimura, Masayuki Endoh, Tadashi Kimura, Tomomi Kotani, Akihiko Sekizawa, Tomoaki Ikeda
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:Journal of Clinical Medicine
Subjects:
fetal growth restriction
tadalafil
phosphodiesterase 5 inhibitor
Online Access:https://www.mdpi.com/2077-0383/8/6/856

Internet

https://www.mdpi.com/2077-0383/8/6/856

Similar Items